Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
Winkelmayer WC, Lensing AWA, Thadhani RI, Mahaffey KW, Walsh M, Pap ÁF, Willmann S, Thelen K, Hodge S, Solms A, Ingham SJM, Eikelboom J; RE-THINC investigators. Winkelmayer WC, et al. Among authors: solms a. Kidney Int. 2024 Mar 26:S0085-2538(24)00196-0. doi: 10.1016/j.kint.2024.02.024. Online ahead of print. Kidney Int. 2024. PMID: 38537676
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Reinecke I, Solms A, Willmann S, Spiro TE, Peters G, Weitz JI, Mueck W, Garmann D, Schmidt S, Zhang L, Fox KAA, Berkowitz SD. Reinecke I, et al. Among authors: solms a. J Thromb Thrombolysis. 2020 Jul;50(1):12-19. doi: 10.1007/s11239-020-02078-8. J Thromb Thrombolysis. 2020. PMID: 32323190 Free PMC article. Clinical Trial.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Solms A, Willmann S, Reinecke I, Spiro TE, Peters G, Weitz JI, Mueck W, Garmann D, Schmidt S, Zhang L, Fox KAA, Berkowitz SD. Solms A, et al. J Thromb Thrombolysis. 2020 Jul;50(1):1-11. doi: 10.1007/s11239-020-02073-z. J Thromb Thrombolysis. 2020. PMID: 32323191 Free PMC article. Clinical Trial.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
Zhang L, Yan X, Fox KAA, Willmann S, Nandy P, Berkowitz SD, Hermanowski-Vosatka A, Weitz JI, Solms A, Schmidt S, Patel M, Peters G. Zhang L, et al. Among authors: solms a. J Thromb Thrombolysis. 2020 Jul;50(1):20-29. doi: 10.1007/s11239-020-02077-9. J Thromb Thrombolysis. 2020. PMID: 32323192 Free PMC article. Clinical Trial.
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AWA, Bethune C, Morgan E, Yu RZ, Wang Y, Jung SW, Geary R, Bhanot S. Willmann S, et al. Among authors: solms a. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):890-901. doi: 10.1002/psp4.12663. Epub 2021 Jun 23. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34085768 Free PMC article.
29 results